BRPI0608310A2 - uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos - Google Patents

uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos

Info

Publication number
BRPI0608310A2
BRPI0608310A2 BRPI0608310-2A BRPI0608310A BRPI0608310A2 BR PI0608310 A2 BRPI0608310 A2 BR PI0608310A2 BR PI0608310 A BRPI0608310 A BR PI0608310A BR PI0608310 A2 BRPI0608310 A2 BR PI0608310A2
Authority
BR
Brazil
Prior art keywords
poxvirus
rapid induction
animal
modified
human
Prior art date
Application number
BRPI0608310-2A
Other languages
English (en)
Inventor
Luis Mateo
Paul Chaplin
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0608310(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of BRPI0608310A2 publication Critical patent/BRPI0608310A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UM POXVIRUS MODIFICADO PARA A INDUçãO RáPIDA DE IMUNIDADE CONTRA UM POXVìRUS OU OUTROS AGENTES INFECCIOSOS. A presente invenção refere-se à indução rápida de uma resposta imune protetora contra poxvirus e infecções por poxvirus tal como varíola por vacinação de um animal, inclusive um ser humano com um poxvírus que não é competente para replicação no dito animal inclusive o ser humano. Um exemplo de tal poxvírus é um vírus da Vacínia Modificada Ankara (MVA). A invenção refere-se adicionalmente ao uso de um poxvírus recombinante que não é competente para replicação no animal, inclusive o ser humano que é vacinado com o vírus, tal como uma MVA recombinante que expressa antigenos heterólogos e/ou epítopos antigênicos para uma indução rápida de respostas imunes protetoras contra o dito antigeno heterólogo e/ou epítopo antigênico, por exemplo, contra um antigeno e/ou epítopo antigênico que faz parte de um agente infeccioso.
BRPI0608310-2A 2005-02-23 2006-02-17 uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos BRPI0608310A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003873 2005-02-23
PCT/EP2006/001447 WO2006089690A1 (en) 2005-02-23 2006-02-17 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents

Publications (1)

Publication Number Publication Date
BRPI0608310A2 true BRPI0608310A2 (pt) 2009-12-08

Family

ID=34933889

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608310-2A BRPI0608310A2 (pt) 2005-02-23 2006-02-17 uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos

Country Status (25)

Country Link
US (3) US20110142877A1 (pt)
EP (1) EP1855720B2 (pt)
JP (3) JP2008531489A (pt)
KR (1) KR20070110007A (pt)
CN (1) CN101128217B (pt)
AU (1) AU2006218115B2 (pt)
BR (1) BRPI0608310A2 (pt)
CA (1) CA2593532C (pt)
CY (1) CY1118573T1 (pt)
DK (1) DK1855720T4 (pt)
EA (1) EA013404B1 (pt)
ES (1) ES2608627T5 (pt)
FI (1) FI1855720T4 (pt)
HU (1) HUE030037T2 (pt)
IL (1) IL184347A (pt)
LT (1) LT1855720T (pt)
MX (1) MX2007010158A (pt)
MY (1) MY162027A (pt)
NO (1) NO347468B1 (pt)
NZ (1) NZ556409A (pt)
PT (1) PT1855720T (pt)
SI (1) SI1855720T2 (pt)
UA (1) UA100836C2 (pt)
WO (1) WO2006089690A1 (pt)
ZA (1) ZA200706078B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100836C2 (ru) 2005-02-23 2013-02-11 Бавариан Нордик А/С Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
DK2596801T3 (en) 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
KR102269491B1 (ko) * 2013-03-15 2021-06-25 버베리안 노딕 에이/에스 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도
US10653766B2 (en) 2014-03-12 2020-05-19 Bavarian Nordic A/S Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0015491A (pt) * 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
CN100540051C (zh) 2002-04-19 2009-09-16 巴法里安诺迪克有限公司 用于接种新生儿的改良的安卡拉痘苗病毒
ATE315660T1 (de) * 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
ES2305514T5 (es) † 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
CA2511625A1 (en) * 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
EP2363143A3 (en) * 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
UA100836C2 (ru) * 2005-02-23 2013-02-11 Бавариан Нордик А/С Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA

Also Published As

Publication number Publication date
MY162027A (en) 2017-05-31
IL184347A0 (en) 2007-10-31
PT1855720T (pt) 2016-12-14
JP2008531489A (ja) 2008-08-14
CN101128217B (zh) 2012-04-25
WO2006089690A9 (en) 2012-10-04
FI1855720T4 (fi) 2023-08-31
JP5952112B2 (ja) 2016-07-13
WO2006089690A1 (en) 2006-08-31
UA100836C2 (ru) 2013-02-11
EA200701801A1 (ru) 2008-02-28
KR20070110007A (ko) 2007-11-15
CN101128217A (zh) 2008-02-20
LT1855720T (lt) 2017-01-10
US8808709B2 (en) 2014-08-19
JP2016104822A (ja) 2016-06-09
US9265823B2 (en) 2016-02-23
ES2608627T5 (es) 2023-10-04
NZ556409A (en) 2010-09-30
EP1855720B2 (en) 2023-04-26
DK1855720T4 (da) 2023-07-24
NO20074855L (no) 2007-10-26
US20140341946A1 (en) 2014-11-20
ES2608627T3 (es) 2017-04-12
CA2593532A1 (en) 2006-08-31
MX2007010158A (es) 2007-10-16
IL184347A (en) 2016-07-31
SI1855720T2 (sl) 2023-07-31
ZA200706078B (en) 2012-10-31
NO347468B1 (no) 2023-11-13
EP1855720A1 (en) 2007-11-21
SI1855720T1 (sl) 2017-01-31
CA2593532C (en) 2017-05-02
CY1118573T1 (el) 2017-07-12
EA013404B1 (ru) 2010-04-30
DK1855720T3 (da) 2017-01-16
JP2012193198A (ja) 2012-10-11
HK1113466A1 (en) 2008-10-03
AU2006218115A1 (en) 2006-08-31
HUE030037T2 (en) 2017-04-28
US20120107359A1 (en) 2012-05-03
AU2006218115B2 (en) 2012-08-02
EP1855720B1 (en) 2016-10-05
US20110142877A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CY1118573T1 (el) Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
JOP20220349A1 (ar) توليفة لقاح ضد الإصابة بفيروس مخلوي تنفسي
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
PH12018502403A1 (en) Hiv vaccine formulation
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
DK1968632T3 (da) Forbedret influenzavaccine
MX388128B (es) Vacuna combinada para cerdos.
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
BR112021025172A2 (pt) Proteínas de fusão para vacinas de tuberculose
WO2017142843A8 (en) Novel antigen for use in malaria vaccine
BR112014023414A2 (pt) vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
MX2022012647A (es) Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX2022003090A (es) Vacuna combinada para ser administrable intradermicamente.
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
DK1387693T3 (da) Saponininaktiveret mykoplasmavaccine
BR112022000347A2 (pt) Vacinas de ehrlichia e composições imunogênicas
BR0115095A (pt) Composição de vacina, e, método para induzir uma resposta imune em um ruminante para prover proteção imune que reduz a severidade de ou infecção por a. marginale

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL